HC Wainwright Has Optimistic Outlook of APRE FY2024 Earnings

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Aprea Therapeutics in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($2.39) per share for the year, up from their prior estimate of ($2.41). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q4 2024 earnings at ($0.54) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.61) EPS.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research report on Tuesday, August 13th.

Aprea Therapeutics Stock Down 2.9 %

NASDAQ APRE opened at $2.92 on Wednesday. The firm’s 50 day moving average is $3.31 and its 200-day moving average is $3.84. The company has a market capitalization of $15.87 million, a PE ratio of -1.04 and a beta of 0.97. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.11. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.45 million.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned 0.20% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Aprea Therapeutics

In other news, Director Bernd R. Seizinger bought 10,000 shares of the company’s stock in a transaction dated Friday, October 11th. The shares were bought at an average cost of $2.68 per share, with a total value of $26,800.00. Following the acquisition, the director now owns 44,730 shares in the company, valued at $119,876.40. This trade represents a 28.79 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Marc Duey sold 6,462 shares of Aprea Therapeutics stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $4.58, for a total value of $29,595.96. Following the transaction, the director now owns 233,651 shares of the company’s stock, valued at $1,070,121.58. The trade was a 2.69 % decrease in their position. The disclosure for this sale can be found here. Insiders purchased a total of 42,290 shares of company stock worth $165,096 over the last ninety days. 12.80% of the stock is currently owned by corporate insiders.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.